These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 2445779)

  • 1. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
    Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
    J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin.
    Rijken DC; Groeneveld E; Kluft C; Nieuwenhuis HK
    Biochem J; 1988 Oct; 255(2):609-15. PubMed ID: 2974279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin.
    Kluft C; Vellenga E; Brommer EJ; Wijngaards G
    Blood; 1982 Jun; 59(6):1169-80. PubMed ID: 6177359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild haemostatic problems associated with congenital heterozygous alpha 2-antiplasmin deficiency.
    Leebeek FW; Stibbe J; Knot EA; Kluft C; Gomes MJ; Beudeker M
    Thromb Haemost; 1988 Feb; 59(1):96-100. PubMed ID: 3363537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha 2-antiplasmin: functional characterization and metabolism in a heterozygote deficient patient.
    Knot EA; ten Cate JW; Lamping RJ; Gie LK
    Thromb Haemost; 1986 Jun; 55(3):375-8. PubMed ID: 3750266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.
    Carpenter SL; Mathew P
    Haemophilia; 2008 Nov; 14(6):1250-4. PubMed ID: 19141165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin.
    Angles-Cano E; Rouy D; Lijnen HR
    Biochim Biophys Acta; 1992 Dec; 1156(1):34-42. PubMed ID: 1472536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA; Booth NA; Croll AM; Bennett B
    Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
    Sakata Y; Aoki N
    J Clin Invest; 1980 Feb; 65(2):290-7. PubMed ID: 6444305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1.
    Dewerchin M; Collen D; Lijnen HR
    Thromb Haemost; 2001 Aug; 86(2):640-6. PubMed ID: 11522016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hemorrhagic syndrome and isolated alpha 2-antiplasmin deficiency. Apropos of a case].
    Guermazi S; Khelif A; Conrad J; Ennabli S; Dellagi K
    Pathol Biol (Paris); 1997 Jun; 45(6):483-6. PubMed ID: 9309264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic variation of plasminogen activation in human uterine fluid and the influence of an intrauterine device.
    Casslén B; Ohlsson K
    Acta Obstet Gynecol Scand; 1981; 60(2):97-101. PubMed ID: 6454324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis.
    Scharrer IM; Wohl RC; Hach V; Sinio L; Boreisha I; Robbins KC
    Thromb Haemost; 1986 Jun; 55(3):396-401. PubMed ID: 2944241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited disorders of the fibrinolytic pathway.
    Jain S; Acharya SS
    Transfus Apher Sci; 2019 Oct; 58(5):572-577. PubMed ID: 31427261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The suitability of various plasmin preparations for the functional assay of alpha 2-antiplasmin in plasma.
    Kluft C; Traas DW; Jie AF; Hoegee-de Nobel E
    Thromb Haemost; 1982 Dec; 48(3):320-4. PubMed ID: 6219471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A.
    Crum ED; Shainoff JR; Graham RC; Ratnoff OD
    J Clin Invest; 1974 May; 53(5):1308-19. PubMed ID: 4856883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.